Mednax Inc (MD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mednax Inc stock (MD) is currently trading at $21.19. Mednax Inc PE ratio is 10.92. Mednax Inc PS ratio (Price-to-Sales) is 0.95. Analyst consensus price target for MD is $21.33. WallStSmart rates MD as Moderate Buy.
- MD PE ratio analysis and historical PE chart
- MD PS ratio (Price-to-Sales) history and trend
- MD intrinsic value — DCF, Graham Number, EPV models
- MD stock price prediction 2025 2026 2027 2028 2029 2030
- MD fair value vs current price
- MD insider transactions and insider buying
- Is MD undervalued or overvalued?
- Mednax Inc financial analysis — revenue, earnings, cash flow
- MD Piotroski F-Score and Altman Z-Score
- MD analyst price target and Smart Rating
Mednax Inc
📊 No data available
Try selecting a different time range
MD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Mednax Inc (MD)
MD trades at a significant discount to its Graham intrinsic value of $48.58, offering a 56% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Mednax Inc (MD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, price/sales. Concerns around revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Mednax Inc (MD) Key Strengths (5)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
104.23% of shares held by major funds and institutions
Every $100 of equity generates $20 in profit
Trading at 1.89x book value, attractively priced
Supporting Valuation Data
Mednax Inc (MD) Areas to Watch (5)
Revenue declining -1.70%, a shrinking business
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Solid earnings growth at 11.40%
Mednax Inc (MD) Detailed Analysis Report
Overall Assessment
This company scores 67/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 3.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Institutional Own.. Valuation metrics including PEG Ratio (0.24), Price/Sales (0.95), Price/Book (1.89) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 20.30%.
The Bear Case
The primary concerns are Revenue Growth, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at -1.70%, EPS Growth at 11.40%, which may limit upside. Profitability pressure is visible in Operating Margin at 11.10%, Profit Margin at 8.64%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 20.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -1.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (Revenue Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MD's Price-to-Sales ratio of 0.95x trades at a deep discount to its historical average of 3.53x (5th percentile). The current valuation is 93% below its historical high of 12.71x set in Mar 2006, and 22% above its historical low of 0.78x in Jan 2019.
WallStSmart Analysis Synopsis
Data-driven financial summary for Mednax Inc (MD) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Mednax Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1.9B with 2% decline year-over-year. Profit margins are thin at 8.6%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 20.3% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 109M in free cash flow and 114M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Mednax Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Mednax Inc.
Bottom Line
Mednax Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(3 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:33:42 AM
About Mednax Inc(MD)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.